Company Generex Biotechnology Corporation Other OTC
Equities
GNBT
US3714853013
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2019 | Weight | 2020 | Weight | Delta |
---|---|---|---|---|---|
Drug Delivery Systems and Technologies
99.3
%
| - | - | 3 | 99.3 % | - |
Management Services
0.7
%
| - | - | 0 | 0.7 % | - |
Sales per region
USD in Million | 2019 | Weight | 2020 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 3 | 100.0 % | -57.10% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joseph Moscato
CEO | Chief Executive Officer | 61 | 21/17/21 |
Mark Carrao
DFI | Director of Finance/CFO | - | 01/17/01 |
Terry Thompson
COO | Chief Operating Officer | 65 | 25/18/25 |
Andrew Ro
CIO | Chief Investment Officer | 54 | 21/17/21 |
Chief Administrative Officer | 54 | 12/18/12 | |
Jason Terrell
CTO | Chief Tech/Sci/R&D Officer | 43 | 01/17/01 |
General Counsel | - | 12/19/12 | |
Michelle Starr
SAM | Sales & Marketing | - | 08/19/08 |
Corporate Officer/Principal | - | 08/19/08 | |
Eric von Hofe
PRN | Corporate Officer/Principal | 66 | 01/05/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Brian T. McGee
BRD | Director/Board Member | 63 | 01/04/01 |
Eric von Hofe
PRN | Corporate Officer/Principal | 66 | 01/05/01 |
Craig Eagle
BRD | Director/Board Member | 57 | 21/17/21 |
Joseph Moscato
CEO | Chief Executive Officer | 61 | 21/17/21 |
Andrew Ro
CIO | Chief Investment Officer | 54 | 21/17/21 |
Director/Board Member | 73 | 08/19/08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 122,058,444 | 122,058,444 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |